HALIFAX, Nov. 2, 2012 /CNW/ - MedMira Inc., (MedMira)
(TSXV: MIR), a developer of rapid diagnostic technology and
solutions, has launched a new brand identity for the Company along
with a redesigned website at www.medmira.com.
MedMira's new brand identity is designed to
reflect its innovative mindset and its core focus on technology and
high quality testing solutions. The logo symbol identifies
with the Company name and the unique vertical flow-through
technology that sets MedMira apart from other rapid diagnostics
companies. The symbol also illustrates the advanced multiplex
capabilities of MedMira's rapid testing solutions that deliver a
minimum three test results on a single device. The new
identity will also be applied to the Company's product portfolio of
rapid testing solutions.
"We are proud to introduce this unique wordmark
and symbol as part of our brand identity as it reflects the quality
of our world class rapid vertical flow-through diagnostic
technology and testing solutions," said Hermes Chan, CEO. "Our new look represents
a key piece in a strategic transformation for the Company, as we go
forward with a solid technology and product focus to deliver
advanced rapid testing solutions to customers and value to our
shareholders."
A central piece in MedMira's brand evolution is
the redesigned and upgraded Company website, which boasts a new,
modern look as well as quick and easy access to more in-depth
product and company information. The new site includes
product demonstration videos that illustrate how to use MedMira's
rapid testing solutions in various environments, including point of
care, laboratories and batch testing settings. These new
videos are key sales and training tools for MedMira's partners and
customers. The new website also includes an enriched section
for investors, with an extensive Investor Kit. MedMira worked
with the digital marketing agency, Headspace Design
(www.headspacedesign.ca), to develop the new identity and
website.
Chan added, "Working with partners, customers
and key stakeholders around the world, we understand the importance
of providing information about our products and our Company
online. With this in mind we have launched our redesigned
website to provide straightforward and relevant information about
MedMira, our technology and products to a broad range of audiences,
from customers to investors, to collaborators."
About MedMira
MedMira is a leading developer and manufacturer
of flow-through rapid diagnostics and technologies. The Company's
testing solutions provide hospitals, labs, clinics and individuals
with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold
under the Reveal®, Multiplo™ and Miriad brands in global markets.
MedMira's rapid flow-through HIV test is the only one in the world
to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit MedMira's website
at www.medmira.com.
This news release contains forward-looking
statements, including statements relating to growth in the
Company's business, earnings and profitability, and trends in
demand for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.